Home LiteratureArticle Details
PMID: 22837873 Published · ppublish English Journal Article

An Update on Post-infectious Irritable Bowel Syndrome: Role of Genetics, Immune Activation, Serotonin and Altered Microbiome.

Journal of neurogastroenterology and motility ·Vol. 18 ·No. 3 ·2012-07-00 ·Pages 258-68

Spiller R, Lam C

Abstract

The literature on post-infectious irritable bowel syndrome (IBS) is reviewed with special emphasis on recent new data. Further accounts of this phenomenon continue to be reported following a range of infections including giardiasis as well as viral and bacterial gastroenteritis. Risk factors such as severity of initial illness, female gender together with adverse psychological factors have been confirmed. Recent evidence of a genetic predisposition needs replication. Animal studies suggest activation of mast cells and inflammation driven impairment of serotonin transporter may be important, which are findings supported by some recent human studies in IBS with diarrhoea. Experimentally induced inflammation leads to damage and remodelling of enteric nerves. Similar changes have been reported in IBS patients with increase in nerves expressing transient receptor potential cation channel V1. While changes in microbiota are very likely this area has yet to be explored using modern techniques. Since the prognosis is for slow improvement, treatments should currently target the key symptoms of diarrhoea and abdominal pain. Future therapies aimed at correcting underlying mechanisms including immune activation and serotonin excess are currently being explored and may provide better treatments in the future.

Keywords
Genetics Infection Irritable bowel syndrome Serotonin
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Spiller Robin
NIHR Biomedical Research Unit in the Nottingham Digestive Diseases Centre, Nottingham, United Kingdom.
Lam Ching
References (115)
115 references, click to expand
  1. Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome.
    Gastroenterology. 2002 Dec;123(6):1972-9 PMID: 12454854
  2. Dyspepsia and irritable bowel syndrome after a Salmonella gastroenteritis outbreak: one-year follow-up cohort study.
    Gastroenterology. 2005 Jul;129(1):98-104 PMID: 16012939
  3. CRF1 receptor signaling pathways are involved in stress-related alterations of colonic function and viscerosensitivity: implications for irritable bowel syndrome.
    Br J Pharmacol. 2004 Apr;141(8):1321-30 PMID: 15100165
  4. Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials.
    Neurogastroenterol Motil. 2003 Feb;15(1):79-86 PMID: 12588472
  5. Systematic review and meta-analysis: The incidence and prognosis of post-infectious irritable bowel syndrome.
    Aliment Pharmacol Ther. 2007 Aug 15;26(4):535-44 PMID: 17661757
  6. Guidelines on the irritable bowel syndrome: mechanisms and practical management.
    Gut. 2007 Dec;56(12):1770-98 PMID: 17488783
  7. Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients.
    BMJ. 1997 Mar 15;314(7083):779-82 PMID: 9080994
  8. The alteration of enterochromaffin cell, mast cell, and lamina propria T lymphocyte numbers in irritable bowel syndrome and its relationship with psychological factors.
    J Gastroenterol Hepatol. 2008 Nov;23(11):1689-94 PMID: 19120860
  9. Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials.
    Clin Gastroenterol Hepatol. 2008 May;6(5):545-55 PMID: 18242143
  10. Increased levels of substance P in the myenteric plexus of Trichinella-infected rats.
    Gastroenterology. 1992 Jun;102(6):1913-9 PMID: 1375178
  11. The tryptophan hydroxylase inhibitor LX1031 shows clinical benefit in patients with nonconstipating irritable bowel syndrome.
    Gastroenterology. 2011 Aug;141(2):507-16 PMID: 21684281
  12. Stress-induced visceral hypersensitivity to rectal distension in rats: role of CRF and mast cells.
    Neurogastroenterol Motil. 1997 Dec;9(4):271-9 PMID: 9430796
  13. Intestinal serotonin release, sensory neuron activation, and abdominal pain in irritable bowel syndrome.
    Am J Gastroenterol. 2011 Jul;106(7):1290-8 PMID: 21427712
  14. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome.
    Gastroenterology. 2004 Mar;126(3):693-702 PMID: 14988823
  15. Enhanced cholinergic-mediated increase in the pro-inflammatory cytokine IL-6 in irritable bowel syndrome: role of muscarinic receptors.
    Am J Gastroenterol. 2008 Oct;103(10):2570-6 PMID: 18785949
  16. Bacterial succession in the colon during childhood and adolescence: molecular studies in a southern Indian village.
    Am J Clin Nutr. 2008 Dec;88(6):1643-7 PMID: 19064526
  17. The colon in shigellosis: serial colonoscopic appearances in Shigella dysenteriae I.
    Endoscopy. 1990 Jan;22(1):35-8 PMID: 2407526
  18. Effect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: a randomized controlled proof-of-concept study.
    Aliment Pharmacol Ther. 2009 Aug;30(3):245-52 PMID: 19438846
  19. Combination of allergic factors can worsen diarrheic irritable bowel syndrome: role of barrier defects and mast cells.
    Am J Gastroenterol. 2012 Jan;107(1):75-81 PMID: 21931380
  20. Terminal ileal mucosal mast cells in irritable bowel syndrome.
    Dig Dis Sci. 1993 Sep;38(9):1590-5 PMID: 8359068
  21. The vanilloid receptor initiates and maintains colonic hypersensitivity induced by neonatal colon irritation in rats.
    Gastroenterology. 2007 Feb;132(2):615-27 PMID: 17258716
  22. Psychological stress activates interleukin-1beta gene expression in human mononuclear cells.
    Brain Behav Immun. 2005 Nov;19(6):540-6 PMID: 16214025
  23. Enhancing effect of corticotropin-releasing neurohormone on the production of interleukin-1 and interleukin-2.
    Neurosci Lett. 1990 Dec 11;120(2):151-4 PMID: 2293102
  24. Increased rectal mucosal expression of interleukin 1beta in recently acquired post-infectious irritable bowel syndrome.
    Gut. 2003 Apr;52(4):523-6 PMID: 12631663
  25. Genetic influences in irritable bowel syndrome: a twin study.
    Am J Gastroenterol. 2005 Jun;100(6):1340-4 PMID: 15929767
  26. The cognitive behavioural model of irritable bowel syndrome: a prospective investigation of patients with gastroenteritis.
    Gut. 2007 Aug;56(8):1066-71 PMID: 17324974
  27. Randomized, double-blind, placebo-controlled trial of prednisolone in post-infectious irritable bowel syndrome.
    Aliment Pharmacol Ther. 2003 Jul 1;18(1):77-84 PMID: 12848628
  28. Microbial community analysis reveals high level phylogenetic alterations in the overall gastrointestinal microbiota of diarrhoea-predominant irritable bowel syndrome sufferers.
    BMC Gastroenterol. 2009 Dec 17;9:95 PMID: 20015409
  29. The irritable colon syndrome. A study of the clinical features, predisposing causes, and prognosis in 130 cases.
    Q J Med. 1962 Jul;31:307-22 PMID: 13878459
  30. Monitoring of stool microbiota in subjects with diarrhea indicates distortions in composition.
    J Clin Microbiol. 2006 Dec;44(12):4550-2 PMID: 17021054
  31. Post Salmonella irritable bowel syndrome--5 year review.
    J Infect. 1996 Mar;32(2):170-1 PMID: 8708382
  32. Longitudinal study of infectious intestinal disease in the UK (IID2 study): incidence in the community and presenting to general practice.
    Gut. 2012 Jan;61(1):69-77 PMID: 21708822
  33. Distribution and spread of colonic lesions in shigellosis: a colonoscopic study.
    J Infect Dis. 1984 Dec;150(6):899-903 PMID: 6501931
  34. Visceral hyperalgesia and intestinal dysmotility in a mouse model of postinfective gut dysfunction.
    Gastroenterology. 2004 Jul;127(1):179-87 PMID: 15236184
  35. Prognosis in post-infective irritable bowel syndrome: a six year follow up study.
    Gut. 2002 Sep;51(3):410-3 PMID: 12171965
  36. Evidence of a genetic contribution to functional bowel disorder.
    Am J Gastroenterol. 1998 Aug;93(8):1311-7 PMID: 9707057
  37. T-cell activation in patients with irritable bowel syndrome.
    Am J Gastroenterol. 2009 May;104(5):1205-12 PMID: 19367268
  38. Pathogenic mechanisms of postinfectious functional gastrointestinal disorders: results 3 years after gastroenteritis.
    Scand J Gastroenterol. 2009;44(10):1173-85 PMID: 19711225
  39. Brain-gut interactions increase peripheral nociceptive signaling in mice with postinfectious irritable bowel syndrome.
    Gastroenterology. 2011 Dec;141(6):2098-2108.e5 PMID: 21856270
  40. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome.
    Gut. 2000 Dec;47(6):804-11 PMID: 11076879
  41. A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndrome.
    Scand J Gastroenterol. 2008;43(10):1202-11 PMID: 18618371
  42. The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome.
    Gut. 2010 Sep;59(9):1213-21 PMID: 20650926
  43. Development of functional gastrointestinal disorders after Giardia lamblia infection.
    BMC Gastroenterol. 2009 Apr 21;9:27 PMID: 19383162
  44. Treatment of postinfectious irritable bowel syndrome and noninfective irritable bowel syndrome with mesalazine.
    Arq Gastroenterol. 2011 Jan-Mar;48(1):36-40 PMID: 21537540
  45. Activation of human enteric neurons by supernatants of colonic biopsy specimens from patients with irritable bowel syndrome.
    Gastroenterology. 2009 Oct;137(4):1425-34 PMID: 19596012
  46. In vivo effects of the 5-HT3 antagonist alosetron on basal and cholera toxin-induced secretion in the human jejunum: a segmental perfusion study.
    Aliment Pharmacol Ther. 1997 Dec;11(6):1109-14 PMID: 9663837
  47. Activation of the mucosal immune system in irritable bowel syndrome.
    Gastroenterology. 2002 Jun;122(7):1778-83 PMID: 12055584
  48. Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker?
    Gastroenterology. 2006 Feb;130(2):304-11 PMID: 16472586
  49. Immune activation in patients with irritable bowel syndrome.
    Gastroenterology. 2007 Mar;132(3):913-20 PMID: 17383420
  50. Effect of bowel preparation and colonoscopy on post-procedure intestinal microbiota composition.
    Gut. 2006 Dec;55(12):1822-3 PMID: 17124165
  51. Intestinal microecology and quality of life in irritable bowel syndrome patients.
    World J Gastroenterol. 2004 Jun 15;10(12):1802-5 PMID: 15188510
  52. Pharmacology of the new treatments for lower gastrointestinal motility disorders and irritable bowel syndrome.
    Clin Pharmacol Ther. 2012 Jan;91(1):44-59 PMID: 22071696
  53. Mucosal mast cell counts correlate with visceral hypersensitivity in patients with diarrhea predominant irritable bowel syndrome.
    J Gastroenterol Hepatol. 2006 Jan;21(1 Pt 1):71-8 PMID: 16706815
  54. Increased mast cells in the irritable bowel syndrome.
    Neurogastroenterol Motil. 2000 Oct;12(5):449-57 PMID: 11012945
  55. Role of nerves in enteric infection.
    Gut. 2002 Dec;51(6):759-62 PMID: 12427768
  56. Irritable bowel syndrome in twins: heredity and social learning both contribute to etiology.
    Gastroenterology. 2001 Oct;121(4):799-804 PMID: 11606493
  57. Release of mast cell mediators into the jejunum by cold pain stress in humans.
    Gastroenterology. 1998 Apr;114(4):640-8 PMID: 9516384
  58. Role of tumor necrosis factor-alpha and interleukin-10 gene polymorphisms in irritable bowel syndrome.
    Am J Gastroenterol. 2005 Nov;100(11):2510-6 PMID: 16279907
  59. Distribution of calcitonin gene-related peptide, somatostatin, substance P and vasoactive intestinal polypeptide in experimental colitis in rats.
    Neurogastroenterol Motil. 1998 Aug;10(4):315-29 PMID: 9697106
  60. Physicochemical characteristics and flora of diarrhoeal and recovery faeces in children with acute gastro-enteritis in Kenya.
    Ann Trop Paediatr. 1990;10(4):339-45 PMID: 1708960
  61. Enterochromaffin cell and 5-hydroxytryptamine responses to the same infectious agent differ in Th1 and Th2 dominant environments.
    Gut. 2008 Apr;57(4):475-81 PMID: 18198200
  62. The role of psychological and biological factors in postinfective gut dysfunction.
    Gut. 1999 Mar;44(3):400-6 PMID: 10026328
  63. Enterochromaffin cell hyperplasia and decreased serotonin transporter in a mouse model of postinfectious bowel dysfunction.
    Neurogastroenterol Motil. 2005 Dec;17(6):863-70 PMID: 16336502
  64. IFN-gamma and TNF-alpha decrease serotonin transporter function and expression in Caco2 cells.
    Am J Physiol Gastrointest Liver Physiol. 2007 Mar;292(3):G779-84 PMID: 17170025
  65. CD4+ T cell-mediated immunological control of enterochromaffin cell hyperplasia and 5-hydroxytryptamine production in enteric infection.
    Gut. 2007 Jul;56(7):949-57 PMID: 17303597
  66. Study of infectious intestinal disease in England: rates in the community, presenting to general practice, and reported to national surveillance. The Infectious Intestinal Disease Study Executive.
    BMJ. 1999 Apr 17;318(7190):1046-50 PMID: 10205103
  67. Role of immunologic factors and cyclooxygenase 2 in persistent postinfective enteric muscle dysfunction in mice.
    Gastroenterology. 2001 Jun;120(7):1729-36 PMID: 11375954
  68. Characteristics of patients with irritable bowel syndrome recruited from three sources: implications for clinical trials.
    Aliment Pharmacol Ther. 2001 Jul;15(7):959-64 PMID: 11421870
  69. Functional bowel disorders.
    Gastroenterology. 2006 Apr;130(5):1480-91 PMID: 16678561
  70. The incidence of irritable bowel syndrome among community subjects with previous acute enteric infection.
    Dig Dis Sci. 2006 May;51(5):1026-32 PMID: 16758307
  71. The fecal microbial population in the irritable bowel syndrome.
    Microbiologica. 1982 Jul;5(3):185-94 PMID: 7121297
  72. Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders.
    Gastroenterology. 2003 Jul;125(1):19-31 PMID: 12851867
  73. A double-blind placebo-controlled trial with loperamide in irritable bowel syndrome.
    Scand J Gastroenterol. 1996 May;31(5):463-8 PMID: 8734343
  74. Post-diarrhea chronic intestinal symptoms and irritable bowel syndrome in North American travelers to Mexico.
    Am J Gastroenterol. 2004 Sep;99(9):1774-8 PMID: 15330917
  75. Distinctive clinical, psychological, and histological features of postinfective irritable bowel syndrome.
    Am J Gastroenterol. 2003 Jul;98(7):1578-83 PMID: 12873581
  76. Relationship of Campylobacter toxigenicity in vitro to the development of postinfectious irritable bowel syndrome.
    J Infect Dis. 2001 Sep 1;184(5):606-9 PMID: 11474430
  77. Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome.
    Gastroenterology. 2007 Jan;132(1):26-37 PMID: 17241857
  78. Association of TNFSF15 polymorphism with irritable bowel syndrome.
    Gut. 2011 Dec;60(12):1671-1677 PMID: 21636646
  79. Postinfectious irritable bowel syndrome after a food-borne outbreak of acute gastroenteritis attributed to a viral pathogen.
    Clin Gastroenterol Hepatol. 2007 Apr;5(4):457-60 PMID: 17289440
  80. Mast cells and cellularity of the colonic mucosa correlated with fatigue and depression in irritable bowel syndrome.
    Gut. 2008 Apr;57(4):468-73 PMID: 18194987
  81. Persistent intestinal neuromuscular dysfunction after acute nematode infection in mice.
    Gastroenterology. 1997 Oct;113(4):1224-32 PMID: 9322517
  82. Eight year prognosis of postinfectious irritable bowel syndrome following waterborne bacterial dysentery.
    Gut. 2010 May;59(5):605-11 PMID: 20427395
  83. Afferent hypersensitivity in a mouse model of post-inflammatory gut dysfunction: role of altered serotonin metabolism.
    J Physiol. 2008 Sep 15;586(18):4517-30 PMID: 18653657
  84. The serotonin signaling system: from basic understanding to drug development for functional GI disorders.
    Gastroenterology. 2007 Jan;132(1):397-414 PMID: 17241888
  85. Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis.
    Gut. 2004 Aug;53(8):1096-101 PMID: 15247174
  86. Stress-related modulation of inflammation in experimental models of bowel disease and post-infectious irritable bowel syndrome: role of corticotropin-releasing factor receptors.
    Brain Behav Immun. 2010 Jan;24(1):41-8 PMID: 19698778
  87. Infectious colitis endoscopically simulating inflammatory bowel disease: a prospective evaluation.
    Gastrointest Endosc. 1983 Aug;29(3):195-7 PMID: 6618115
  88. Stress-induced enhancement of colitis in rats: CRF and arginine vasopressin are not involved.
    Am J Physiol. 1997 Jan;272(1 Pt 1):G84-91 PMID: 9038880
  89. Incidence and epidemiology of irritable bowel syndrome after a large waterborne outbreak of bacterial dysentery.
    Gastroenterology. 2006 Aug;131(2):445-50; quiz 660 PMID: 16890598
  90. Structural and functional changes of the duodenum in human norovirus infection.
    Gut. 2009 Aug;58(8):1070-7 PMID: 19036950
  91. Abnormalities of serotonin metabolism and their relation to symptoms in untreated celiac disease.
    Clin Gastroenterol Hepatol. 2006 Jul;4(7):874-81 PMID: 16797248
  92. Corticotropin releasing factor signaling in colon and ileum: regulation by stress and pathophysiological implications.
    J Physiol Pharmacol. 2009 Dec;60 Suppl 7:33-46 PMID: 20388944
  93. Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum.
    Gut. 2007 Feb;56(2):203-9 PMID: 17005763
  94. Mucosal immune activation in irritable bowel syndrome: gender-dependence and association with digestive symptoms.
    Am J Gastroenterol. 2009 Feb;104(2):392-400 PMID: 19174797
  95. Genetic risk factors for post-infectious irritable bowel syndrome following a waterborne outbreak of gastroenteritis.
    Gastroenterology. 2010 Apr;138(4):1502-13 PMID: 20044998
  96. Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR.
    Am J Gastroenterol. 2005 Feb;100(2):373-82 PMID: 15667495
  97. Microbial-gut interactions in health and disease. Probiotics.
    Best Pract Res Clin Gastroenterol. 2004 Apr;18(2):299-313 PMID: 15123071
  98. Psychometric scores and persistence of irritable bowel after infectious diarrhoea.
    Lancet. 1996 Jan 20;347(8995):150-3 PMID: 8544549
  99. Intestinal mucosal mast cells in normal and nematode-infected rat intestines are in intimate contact with peptidergic nerves.
    Proc Natl Acad Sci U S A. 1987 May;84(9):2975-9 PMID: 2437589
  100. Enterochromaffin cells and 5-HT signaling in the pathophysiology of disorders of gastrointestinal function.
    Curr Opin Investig Drugs. 2004 Jan;5(1):55-60 PMID: 14983974
  101. Mesalazine (5-aminosalicylic acid) alters faecal bacterial profiles, but not mucosal proteolytic activity in diarrhoea-predominant irritable bowel syndrome.
    Aliment Pharmacol Ther. 2011 Aug;34(3):374-83 PMID: 21671966
  102. Impaired uptake of serotonin by platelets from patients with irritable bowel syndrome correlates with duodenal immune activation.
    Gastroenterology. 2011 May;140(5):1434-43.e1 PMID: 21315720
  103. Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome.
    Gastroenterology. 2004 Jun;126(7):1657-64 PMID: 15188158
  104. Prolonged elevation of galanin and tachykinin expression in mucosal and myenteric enteric nerves in trinitrobenzene sulphonic acid colitis.
    Neurogastroenterol Motil. 2008 Apr;20(4):392-406 PMID: 18208479
  105. Corticotropin-releasing hormone augments proinflammatory cytokine production from macrophages in vitro and in lipopolysaccharide-induced endotoxin shock in mice.
    Infect Immun. 2002 Nov;70(11):6068-74 PMID: 12379683
  106. Bacterial hemorrhagic enterocolitis.
    J Gastroenterol. 2003;38(2):111-20 PMID: 12640523
  107. Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS.
    Gastroenterology. 2003 Dec;125(6):1651-9 PMID: 14724817
  108. Activated mast cells infiltrate in close proximity to enteric nerves in diarrhea-predominant irritable bowel syndrome.
    J Korean Med Sci. 2003 Apr;18(2):204-10 PMID: 12692417
  109. How intestinal bacteria cause disease.
    J Infect Dis. 1999 Mar;179 Suppl 2:S331-7 PMID: 10081504
  110. Postinfectious irritable bowel syndrome.
    Gastroenterology. 2009 May;136(6):1979-88 PMID: 19457422
  111. Post inflammatory damage to the enteric nervous system in diverticular disease and its relationship to symptoms.
    Neurogastroenterol Motil. 2009 Aug;21(8):847-e58 PMID: 19453515
  112. Recent advances in understanding the role of serotonin in gastrointestinal motility in functional bowel disorders: alterations in 5-HT signalling and metabolism in human disease.
    Neurogastroenterol Motil. 2007 Aug;19 Suppl 2:25-31 PMID: 17620085
  113. Decreased expression of serotonin in the jejunum and increased numbers of mast cells in the terminal ileum in patients with irritable bowel syndrome.
    World J Gastroenterol. 2007 Dec 7;13(45):6041-7 PMID: 18023097
  114. Increased capsaicin receptor TRPV1-expressing sensory fibres in irritable bowel syndrome and their correlation with abdominal pain.
    Gut. 2008 Jul;57(7):923-9 PMID: 18252749
  115. Risk of irritable bowel syndrome after an episode of bacterial gastroenteritis in general practice: influence of comorbidities.
    Clin Gastroenterol Hepatol. 2007 Apr;5(4):465-9 PMID: 17445753
Article Info
Journal
Journal of neurogastroenterology and motility
Abbr.
J Neurogastroenterol Motil
ISSN
2093-0887
DOI
10.5056/jnm.2012.18.3.258
Published
2012-07-00
Epub
2012-00-10
Pages
258-68
Language
English
Region
Korea (South)
NLM ID
101530189
PMCID
PMC3400813
Grants
Medical Research Council · MC_G1002464 · United Kingdom
External Links
PubMed source DOI: 10.5056/jnm.2012.18.3.258 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2